Acute lymphoblastic leukemia (ALL) is the first hematologic neoplasm for which assessment of early response to therapy using measurable residual disease (MRD) has proven to be a fundamental tool for guiding therapy. It should be a key component in individualizing care to improve outcomes for patients. But MRD is a time point-dependent variable, with different time points signifying different prognosis for relapse. And MRD testing methods are variable across clinical practices, and it can be challenging to select the appropriate combination and sequence of therapy. Consequently, not all patients are provided with uniform care.
During Mastering MRD for Prognosis and Treatment in ALL, experts will discuss conducting MRD testing for patients with ALL according to the guideline-recommended schedule; evaluating the specimens needed for, and the pros and cons of, various methods for assessing MRD; predicting the risk of relapse based on MRD test results; and individualizing treatment based on MRD status to ensure patients at higher risk of relapse receive appropriate risk-adapted therapy. The lunch symposium, brought to you by Medical Learning Institute, Inc. (MLI), will be certified for continuing education credit for physicians, nurses, and pharmacists and will offer American Board of Internal Medicine Maintenance of Certification points. Don’t miss this exciting symposium—REGISTER TODAY to reserve your spot!
This CE activity is intended for hematologic oncology clinicians, nurses, and pharmacists who provide care for individuals with acute lymphoblastic leukemia (ALL).
After completing this CE activity, the participant should be better able to:
- Conduct MRD testing according to the guideline-recommended schedule
- Evaluate the specimens needed for, and the pros and cons of, various methods of assessing MRD
- Predict the risk of relapse based on MRD test results
- Individualize treatment based on MRD status to ensure patients at higher risk of relapse receive appropriate risk-adapted therapy
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.33 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.10 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-069-L01-P
Type of Activity: Knowledge
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
This Independent Satellite Symposium is not an official program of the Society of Hematologic Oncology 2022 Annual Meeting. It is not sponsored or endorsed by the Society of Hematologic Oncology.
Copyright © 2022 Medical Learning Institute, Inc. | All Rights Reserved.
|Welcome, introductions, overview||5 minutes|
|Timing of MRD testing*||10 minutes|
|MRD testing methods*||10 minutes|
|Interpreting results of MRD tests*||15 minutes|
|Using results to guide treatment*||15 minutes|
|Summary of key points, post-test, evaluation, and final Q&A||5 minutes|
*Please note each topic includes a 5 min Q&A
Associate Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
Associate Professor, Department of Hematopathology
Director, Molecular Diagnostic Laboratory – Microarray
The University of Texas MD Anderson Cancer Center
LOCATION & TIME
1600 Lamar, Houston, TX 77010
Level 4, Grand Ballroom DEF
11:32 am – 12:32 pm CDT
This activity is supported by educational funding provided by Amgen.